Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Dose-Escalation and Cohort-Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)

NCT06277219 is registered in ClinicalTrials.gov with Latticon Antibody Therapeutics, Inc as lead sponsor.

NCT NCT06277219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06277219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Dose-Escalation and Cohort-Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)
Lead sponsor
Latticon Antibody Therapeutics, Inc
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 5, 2024
Completion date
March 31, 2027
Enrollment
150 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor